Jasper Therapeutics CEO Jeet Mahal outlined an expanded immunology strategy at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. This strategic shift follows the company’s July merger with Kira Pharmaceuticals.
The company currently maintains approximately $140 million in funding. This capital provides a financial runway expected to last through late 2028.
Management is prioritizing three clinical-stage assets to achieve near-term regulatory milestones. Venosabef recently demonstrated positive Phase II data for paroxysmal nocturnal hemoglobinuria (PNH). Briquilimab shows potential for treating severe combined immunodeficiency.